nkr-2 car-t cells
Cell therapyexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2016 (NCT03018405)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NKG2-D type II integral membrane proteinImmunity, passive
immunity, passive - NKG2D
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nkr-2 cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03612739 | Phase 1 | Oct 31, 2018 | Celyad |
| NCT03466320 | Phase 1 | Sep 30, 2018 | Celyad, Novella Clinical |
| NCT03370198 | Phase 1 | Oct 11, 2017 | Celyad |
| NCT03310008 | Phase 1 | Aug 7, 2017 | Celyad |
| NCT03018405 | Phase 1 | Dec 1, 2016 | Celyad |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celyad | For profit | 5 | 5 | 1 | 2016 |
| Novella Clinical | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1